Aripiprazole Tablet
Product Images NDC 71335-1892

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

This is a table showing the effect of various drugs on aripiprazole, with fold change and 90% C1 values. The drugs include inhibitors and inducers of certain cytochrome P450 enzymes, gastric acid blockers, and other drugs like valproate and lithium. The table also provides a relative change in aripiprazole levels compared to a reference value without the interacting drug.*

FDA Label Image

Figure2 (Figure2)

This text reports the effect of several drugs on Aripiprazole, an antipsychotic medication. The drugs are classified based on their effect on certain liver enzymes, such as CYP3A4 inhibitor ketoconazole or CYP2D6 inhibitor quinidine. The text also mentions the effect of gastric acid blockers like famotidine and other drugs like valproate and lorazepam. The effects are measured by the Fold Change and 90% CI of Dehydro-Aripiprazole. There is a graph showing a change relative to reference without any interacting drug.*

FDA Label Image

Figure3 (Figure3)

The text contains information on the effect of Aripiprazole on other drugs but it is not clear due to some misspelled words, no context and lack of relevant information. Therefore, the description cannot be generated accurately.*

FDA Label Image

Figure4 (Figure4)

This text seems to be a list of parameters related to pharmacokinetics (PK) and drug metabolism in special populations. The parameters include genetic differences in CYP2D6 metabolism ("poor" vs. "extensive" metabolizers), gender, age, and hepatic and renal impairment. The text also mentions avripiprazole fold change and a relative change from a reference value. However, the text contains some errors and incomplete phrases, making it difficult to interpret some of the information.*

FDA Label Image

Figure5 (Figure5)

This seems to be a table depicting a study on the pharmacokinetics of Aripiprazole, a drug used to treat certain mental illnesses. The table compares how the drug is metabolized by individuals with different characteristics such as their CYP2D6 status (poor vs. extensive metabolizer), gender (female vs. male), and age (16-64 vs. >65 years old). Additionally, the table looks at how Aripiprazole is affected by hepatic impairment (mild vs. moderate vs. severe vs. normal) and renal impairment (severe). The last column appears to show the Dehydro-Aripiprazole Fold Change and 90% CI, which may indicate the effectiveness of the drug in each group.*

FDA Label Image

Structure (Structure)

FDA Label Image

Camberlogo (Camber Logo)

FDA Label Image

Figure 6 (Figure 6)

This appears to be a graph showing the proportion of subjects experiencing relapse over time for a drug called Ariplprazole compared to a placebo, with the number of subjects at risk shown below the graph. However, it is not clear what condition the drug is being tested for or any other specific details.*

FDA Label Image

Figure 7 (Figure 7)

This text appears to be a table comprising medication names (Aripiprazole and Placebo), with proportions and the number of subjects at risk. The table also includes the days from randomization, with the number of subjects still under observation at each interval. There is no context provided or indication of what sort of study this data relates to.*

FDA Label Image

Figure 8 (Figure 8)

The text seems to be a table presenting the proportion of relapse for Aripiprazole and Placebo along with the number of subjects at risk for each treatment. The table also includes days from randomization. No further information is available.*

FDA Label Image

Label (Lbl713351892)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.